ClinicalTrials.gg
RecruitingNCT03734900Updated Sep 21, 2026

Comparison of Effectiveness Between PL and PRP on Knee Osteoarthritis: a Prospective,Randomized,Placebo-controlled Trial

A Phase 4 interventional study of Saline injection and PRP injection in Osteoarthritis (OA) of the Knee, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by National Taiwan University Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled May 2018, registered Oct 2018).
  • Started May 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies testing platelet rich plasma in Osteoarthritis — 6 open to participants now, 6 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis.

Planned enrollment
7th of 28
150 · median 70
Started
2018
with 1 other
Phase 4
7 of 28
2 open now
Registered
16th of 28
by date

Among the 28 studies testing platelet rich plasma in Osteoarthritis, this one is the 7th largest by planned enrollment, is one of 2 that started in 2018, is one of 7 in phase 4, and was the 16th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

6 of the 28 studies testing platelet rich plasma in Osteoarthritis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing platelet rich plasma in Osteoarthritis, or all of them as a file.
02

Study summary

This study will focus on grade I to III knee osteoarthritis by randomized controlled trials which comparing the effectiveness between placebo, autologous platelet rich plasma and autologous platelet lysate injections.

Read the detailed description

The current methods for treating knee osteoarthritis include delaying the disease progression and joint replacement surgery. The usual treatment methods are mostly temporary, such as taking drug and hyaluronic acid injection. Therefore, finding the safe and effective methods will greatly reduce medical resource, medical expenses and surgery cost, etc., and restore the patient's quality of life. Platelet lysate is the product of complete activation from autologous platelet. It contains rich growth factors and cytokines such as PDGF, TGF-β, VEGF, EGF and IGF, etc. It can support cell growth and doesn't have any white blood cells in it. It is superior to the platelet rich plasma because of reducing the overall inflammatory response and pain of the patient during treatment.

03

Conditions studied

  • Osteoarthritis (OA) of the Knee

Browse trials for

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 50 to 80 years old
  • Study Subjects must be willing to sign to participate in the study
  • In the past month, at least seven consecutive days in the squat, standing, walking or going up and down the stairs, the most serious degree of visual analogy of the knee pain (Visual Analogue Scale) is greater than or equal to 40 (the most pain is 100, not painful is 0)
  • Morning joint stiffness is less than 30 minutes
  • X-ray:Grade 1-3 radiographic OA as defined by the K-L classification

Exclusion criteria

Exclusion Criteria:

  • Knee instability
  • The knee joint is obviously deformed (> 5 degree valgus or varus deviation on X-ray)
  • Clinical diagnosed as Pes tendinitis, Chondromalacia
  • Taking NSAIDs or (including oral and injection) within one week
  • Using anticoagulant drugs for a long time
  • count is less than 150,000 / UL, or coagulation disorders, (PT value) is less than 11 seconds or greater than 16 seconds
  • Leukemia, sepsis, platelet dysfunction or other blood related diseases
  • tumors, infections or the trauma before the same site
  • Pregnancy
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Placebo comparator
    Saline injection

    Sodium Chloride injection into the study knee joint every 4 weeks for a total of 3 injections

    Other: Saline injection

  • Experimental
    PRP injection

    PRP injection into the study knee joint every 4 weeks for a total of 3 injections

    Biological: PRP injection

  • Experimental
    PL injection

    PL injection into the study knee joint every 4 weeks for a total of 3 injections Platelet lysate is the product of nature activation from autologous platelet.

    Biological: PL injection

Interventions

  • OtherSaline injection

    5ml Placebo infusion of 0.9% Sodium Chloride

  • BiologicalPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Device: "Aeon" Acti-PRP 5ml autologous platelet rich plasma injection

  • BiologicalPL injection

    Device: "Aeon" Acti-PRP 5ml autologous platelet lysate injection

06

What researchers measure

Primary outcomes

  1. Pain score of the patient

    Using Visual Analog Score (from 0 to 10, 0 indicate no pain and 10 indicate maximal pain) to evaluate pain of surgical wound of the patient

    Time frame: up to 24 weeks after surgery

Secondary outcomes

  1. Knee functional score

    Using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Time frame: up to 24 weeks after surgery

  2. X-ray

    Knee X-ray image

    Time frame: up to 24 weeks after surgery

  3. Ultrasonic image

    Ultrasonic-between thickness of the medial and lateral sides of the femoral condyle

    Time frame: up to 24 weeks after surgery

  4. adverse events

    adverse events in clinical trial

    Time frame: up to 24 weeks after surgery

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for May 2027, 107 months after the start.

Of 54 non-industry phase 4 interventional studies under Osteoarthritis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 60. This study's planned 107 months is above that.

Counting every sponsor, half of 63 studies reached it within 28 months; a quarter within 11 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2018
First posted
Nov 8, 2018
StartActual
May 15, 2018
Primary completionEst.
May 14, 2027
CompletionEst.
May 14, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03734900
Responsible party
Sponsor
First posted
Nov 8, 2018
Start date
May 15, 2018
Primary completion
May 14, 2027 (estimated)
Completion
May 14, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

WU Chueh-Hung, MD, CIPS
Contact
nojred@gmail.com
0223123456 ext. 66473
Wang Tyng-Guey, MD
Contact
tgw@ntu.edu.tw
0223123456 ext. 67588
Wu Chueh-Hung, MD, CIPS
study director · National Taiwan University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion